Vioxx Cardiovascular Risk Is Unique To Molecule, Pfizer And Novartis Tell FDA

The cardiovascular safety signal observed in Merck's Vioxx may be caused by the formation of potentially toxic rofecoxib metabolites, Pfizer states in its briefing documents for FDA's upcoming review of COX-2 inhibitors